埃克替尼治疗晚期非小细胞肺癌34例疗效观察

Efficacy of icotinib on 34 patients with advanced non-small-cell lung cancer

目的观察EGFR基因敏感型的晚期非小细胞肺癌患者应用盐酸埃克替尼治疗的短期临床疗效。方法回顾性分析2014-2017年间在我院住院或门诊就诊,应用埃克替尼治疗的34例晚期非小细胞患者的临床资料,所有均经病理活检或细胞学检查证实为腺癌,且经相关检查确诊为进展期(ⅢB-Ⅳ期)。其中男15例,女19例,年龄42～86岁,平均(63. 59±9. 47)岁,无吸烟史20例。观察患者的近期客观有效率、疾病控制率和药物相关不良反应。结果患者的客观有效率为29. 4%,疾病控制率为100. 0%。性别、年龄和吸烟史对药物疗效无影响。患者产生的不良反应主要是胃肠道反应及皮疹,程度均较轻微,无需特殊处理。结论埃克替尼治疗晚期NSCLC具有较好的近期疗效。

Objective To observe the Short-term efficacy of Icotinib in patients with advanced non-small ceil lung cancer with EGFR gene sensitivity.Methods To review the clinical data of 34patients with advanced non-small cell lung cancer therapy treated with Icotinib in our hospital from 2014to 2017,all were confirmed as adenocarcinoma by pathological biopsy or cytologic examination,and were confirmed as advanced stage (stage ⅢB-Ⅳ)by relevant examinations.There were 15males and 19females,aged 42to 86years old,with an average of (63.59±9.47)years old and 20cases without smoking history.Observe the patientg ORR,DCR and drug-related adverse effects.Results The ORR was 29.4%and the DCR was 100.0%.Gender,age,and smoking history had no effect on drug efficacy.The adverse reactions of the patients were mainly gastrointestinal reactions and rashes,all of which were mild and did not require special treatment.Conclusion Icotinib has a good short-term effect in the treatment of advanced NSCLC.